Therapeutic and environmental aromatic amines and hydrazines are substrates for the arylamine N-acetyltransferases (NAT). In all, 10 transgenic lines containing either the human NAT1 or NAT2 transgene were developed using multiple promoters. The presence of the transgene was confirmed by determining copy number, mRNA and enzyme activity. Despite some lines having high copy numbers of the transgene, only modest or no increases in enzymatic activity could be found in a variety of tissues. The NAT1 transgene could not be bred to homozygosity. The cytomegalovirus (CMV)-promoted NAT1 transgene increased endogenous Nat1 mRNA levels in liver and had little effect on endogenous Nat2 mRNA levels. The presence of the CMVpromoted NAT2 transgene appeared to suppress endogenous hepatic Nat2 mRNA, but did not alter Nat1 mRNA levels. The failure to achieve high expression of any of the transgenes suggests that overexpression of NAT genes may have harmful effects during development.
INTRODUCTION
Arylamine N-acetyltransferases (NAT) catalyze the acetylation of the extracyclic amino groups of aromatic amine and hydrazines. Two genes, NAT1 and NAT2, have been isolated and characterized from humans and several animal species. 1 The proteins designated NAT catalyze three types of acetylation reactions: Nacetylation of arylamines, O-acetylation of N-hydroxylamines and the N,Ointramolecular acyl transfer of arylhydroxamic acids. [2] [3] [4] [5] The importance of the NAT isoforms in the biotransformation of environmental chemicals and therapeutic drugs is well recognized. 1 Human NAT1 preferentially catalyzes the acetylation of substrates like p-aminobenzoic acid (PABA), while isoniazid (INH) is a substrate for human NAT2. Carcinogenic aromatic and heterocyclic amines, such as the human carcinogen 4-aminobiphenyl (4ABP), are substrates of both isoforms. Less is known about the physiological significance of these enzymes. Human NAT1 catalyzes the acetylation of a breakdown product of folic acid, paminobenzylglutamate, leading to the suggestion that NAT1 may play an as yet undefined role in folic acid metabolism. 6, 7 Initially, surveys of strains of mice identified variants with high or low PABA Nat activity. 8 Congenic lines were developed using C57Bl/6J, the high-PABA-Natactivity strain, and A/J, the low-activity strain, allowing study of murine Nats on uniform genetic backgrounds. 9 Cloning of mammalian NATs 10 led to identification of a single base pair change distinguishing these two inbred strains. These alleles are designated Nat2*8 and 2*9, resulting in rapid and slow PABA acetylator phenotypes, respectively. 4, 11, 12 C57Bl/ 6J and A/J mice both have the Nat1*6 allele, that is, have genetically identical coding sequences at this locus. Based on amino-acid sequence and substrate specificity, murine Nat2 encodes the Nat isoform that is the functional equivalent of human NAT1, while murine Nat1 resembles human NAT2. [12] [13] [14] [15] [16] There is also evidence of genetic similarity between noncoding exons of human NAT2 and murine Nat2.
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Allelic variation in both NAT1 and NAT2 is generally associated with decreased acetylation in all species evaluated. 1 Although there have been some studies reporting that the NAT1*10 allele results in increased acetylation of PABA, other reports do not support these findings. 18 The Nat2 and the Nat1,2 knockouts have no grossly observable phenotype. 19, 20 Efforts to increase activity of NATs by the addition of transgenes have not been readily achieved. There was a 15-fold increase in sulfamethazine NAT activity in mouse prostate, using the prostate-specific probasin promoter to drive human NAT2. 21 Other NAT2 activities (N-, O-, or N,Oacetyltransferase) were not increased. Human NAT1 with the general human cytomegalovirus (CMV) immediate-early gene promoter was found to have a toxic effect in transgenic embryos. 22 Although a limited number of chimeras were obtained from embryonic stem cells containing replacements of Nat2 by NAT1, there was no germline transmission of the transgene. 22 In the current study, transgenic mice with the human NAT1 or NAT2 gene were obtained with only modest increases in hepatic NAT enzyme activity.
RESULTS

CMV-Promoted NAT1 Transgenics
A series of transgenic founders were obtained with the CMV-NAT1 construct. The number of copies of the transgene varied from 1 to 17 when assayed by real-time PCR (Table 1) . At NX10, of backcrosses to C57BL/6J the human NAT1 mRNA was detected in the liver (Table 1) and lung, kidney and brain (data not shown). The presence of functional protein was determined by measuring NAT activity with PABA, a selective substrate for human NAT1 and murine Nat2 [14] [15] [16] in a variety of tissues (liver, heart, lung, brain, colon and kidney). Statistically significant differences were only seen in liver, with increases ranging from 10 to 50% (Table 1) .
CMV-HAAT-Promoted NAT1 Transgenics
The addition of the liver-specific HAAT promoter to the CMV promoter resulted in two founders, A and B, with five and 24 copies, respectively, of human NAT1. Despite high copy levels in line B, no increase in hepatic acetylation was found at NX3 of backcrosses to C57BL/6J. PABA NAT activities averaged 7.3 nmol product/min/mg for A and 6.870.55 nmol product/min/mg for B, compared to 6.4770.90 nmol product/min/mg for C57Bl/6J.
CMV-Promoted NAT2 Transgenics
Three transgenic founders were obtained with the CMV-NAT2 construct. The number of copies varied from 1 to 5. Moderate amounts of the transgene mRNA were found in liver. Hepatic acetylation measured with the human NAT2/ mouse Nat1 selective substrate INH at NX3 of backcrosses to C57BL/6J showed a two-fold increase compared to the background strain C57Bl/6J (Table 2 ).
Attempts to Breed NAT1
a to Homozygosity It is common to interbreed N12 and beyond congenic lines to create the homozygous line. This was unsuccessful with the NAT1 a transgene on the C57BL/6J background, perhaps due to the intolerance of increased enzyme levels. In all, 11 transgene-positive animals from the intercross were tested for homozygosity by outbreeding and examination of newborns for the transgene (100% expected from a homozygous transgenic). None of the 11 were positive, statistically significantly different from the 1/3 expected from the positives (w 2 , Po0.02). The presence of the NAT1 a (the transgenic line chosen for study) transgene on the C57BL/6J inbred strain led to a 2-3-fold increase in hepatic Nat1 mRNA measured by quantitative real-time RT-PCR (Table 3) . When the NAT2 transgene was studied on the C57BL/6J background, quantitation of endogenous Nat1 showed no significant change in expression of the liver (Table 3 ) and lung, kidney and brain (data not shown). In contrast, Nat2 mRNA was strongly suppressed (six-fold decrease) in the liver (Table 3 ) and other tissues (data not shown).
DISCUSSION
Inbred and congenic strains of mice have been used to investigate the consequences of variation in the acetylation of aromatic amines and hydrazines. 23 Since these models have limitations, efforts have been underway in several laboratories to develop strains over-or underexpressing NAT genes. [19] [20] [21] [22] The current study supports and expands previous work showing that it is very difficult to significantly raise NAT levels using transgenes. Viable animals generally had few copies of the transgene, regardless of whether it was human NAT1 or NAT2 (Tables 1 and 2 ). The NAT1 transgene only increased hepatic PABA NAT activity by 50%, while the NAT2 transgene only increased INH NAT activity by twofold. Attempts to breed the NAT1 a transgene to homozygosity were unsuccessful. This may have been due to intolerance of the higher levels of NAT1 expected. Alternatively, about 5% of transgenic inserts result in autosomal recessive mutations, 24 and an early embryonic lethal gene could have been hit. One explanation for these results is that increased expression of NATs during development may be harmful.
Previous efforts to overexpress the human NAT1 gene using a vector with the CMV promoter resulted in a small number of transgenic mice with many resorbed and malformed embryos. 22 This occurred with both random and targeted insertion. There was a low degree of chimerism in the survivors from the embryonic stem cell replacements, with no germline transmission of the transgene. These results are consistent with development abnormalities. Indeed, the few survivors had very limited chimerism and a defect resulting in a kinky tail, a phenotype sometimes associated with neural tube defects. In contrast, transgenic mice having the human NAT2 transgene with a probasin promoter to target prostrate expression were viable. 21 In this case, the transgene would only be turned on after puberty, avoiding potential developmental problems. The current data further support the notion that overexpression of the NAT genes during development is harmful. Only animals with relatively low levels of expression of the transgene survived. However, the survival rate and germline transmission of the human NAT1 transgene are higher than previously reported, 22 and may reflect strain differences in the mice used by each group.
The basis for the detrimental effects of overexpression of NAT genes during development has yet to be determined. However, excess expression of a combination of the human and mouse genes may be a contributing factor. A folate catabolite, p-aminobenzoylglutamate, is a substrate for human NAT1 and mouse Nat2, 25, 26 and it has been suggested that human NAT1/murine Nat2 plays a yet undefined role in the regulation of folate. 16 Indeed, Nacetyl-p-aminobenzoylglutamate represents more than 80% of p-aminobenzoylglutamate secretion in humans. 27, 28 There are several examples of alterations in folate levels being linked to unwanted effects. It is probable that subsaturation levels of folate are essential for normal transfer of methyl units. When folate cofactors are exchanged between donor and acceptor enzymes, the latter must be unliganded. 29 The negative effects of excess folate concentrations on such enzymatic interchange have been demonstrated in vitro. 30 The toxicity of high levels of folate may also result from its inhibition of RNA binding by some enzymes. In the case of thymidylate synthetase, autoregulation by binding to its own RNA transcript 31 can compete with binding to its ligand, since they both occur at the same site. 32 This being the case, excess folate levels would inhibit this translational autoregulation. Alternatively, increased expression of NAT could lower folate levels. Reduced folate is readily oxidized to the hydropterin and p-aminobenzoylglutamate or polyglutamate, and the polyglutamate polypeptides are hydrolyzed by intracellular gglutamylhydrolase. 33, 34 Thus, excess NAT activity would Nacetylate p-aminobenzoylglutamate to a product that is readily excreted, and presumably decrease folate levels by enhancing this catabolic route.
The consequences of expression of the human NAT transgene on endogenous Nat expression were also investigated. Interestingly, the human NAT2 transgene appeared to decrease the mRNA of Nat2, while the NAT1 transgene increased Nat1 mRNA (Table 4) . Since the results are expressed relative to GAPDH levels, a common 'housekeeping' control, but one that may be influenced by unknown factors, the result must be considered tentative. Human and mouse NATs share considerable sequence homology. Comparison of the C-terminal amino-acid sequences of human NAT1 and mouse Nat2 reveals N-acetyltransferase transgenics W Cao et al significant similarity in the region involved in substrate binding. These isoforms have the same substrate specificities, and human NAT1 is considered to be the functional equivalent of mouse Nat2. [12] [13] [14] [15] [16] Since PABAglu is a substrate for these isoforms, it would be anticipated that overexpression of the human NAT1 transgene may affect expression of the endogenous Nat2 gene, the opposite of what was observed (Table 3) . However, analysis of gene structure reveals that both human and mouse NAT2 have a noncoding exon 6-8 kb upstream of a single coding exon. 17, 35 This has led to the suggestion that murine Nat2 and human NAT2 are genetic orthologs. 17 If so, these genes may be under similar regulatory control, resulting in decreased endogenous murine Nat2 RNA transcription in the presence of the human NAT2 transgene.
Control of the expression of murine and human NAT genes is being investigated in several laboratories. Recent studies have shown a promoter region 245 bases upstream of the coding exon of human NAT1 to be sufficient for basal expression of human NAT1. 36 This region contains an AP1-binding site flanked on both sides by a TCATT motif. There is also a site for binding of Ying Yang 1, with a second promoter region further upstream that is not yet characterized. 36 However, there are two noncoding exons 11.8 and 2.5 kb, respectively, upstream of the coding exon that seem to exert greater regulatory control than the proximate promoter region identified previously. 37 Multiple alternatively spliced transcripts were also demonstrated. NAT substrates induce a luciferase reporter construct of 2943 bp upstream of the coding exon of NAT1, and a construct of 929 bases from the human NAT2 transcription start site. 38 For murine Nat2, analysis of a 13 kb region flanking the coding and noncoding exons showed a single promoter. 38 Potential promoter sequences such as a CAAT box, Sp1-binding site, a hormone response element (HRE) and an AP1 transcription factor-binding site are present. 15 The mouse NAT2 promoter contains an atypical TATA box and Sp1 box, with alterations in either element resulting in decreased activity of the promoter. 39 The presence of AP1-and CREBbinding sites is suggested. 39 As yet, there are no studies on the promoter region of murine Nat1.
In summary, the current data support previous work 22 that overexpression of NAT through the introduction of human NAT1 or NAT2 transgenes is detrimental. Altered expression of the endogenous Nats in the presence of the transgene may contribute to critical imbalances in regulation of folate or other as yet unidentified pathways. Further studies are required to elucidate the mechanism of toxicity associated with increased levels of NATs.
MATERIALS AND METHODS
Generation of Transgenic Mice
The human NAT1 and NAT2 cDNAs had been cloned into the EcoRI and XhoI sites of the mammalian expression vector pcDNA3, which also contains the bovine growth hormone polyadenylation signal. These vectors that have been successfully expressed in cultured cells 40 use the human CMV immediate-early gene 1 promoter/enhancer that leads to high, but variable, expression of a number of recorders. 41, 42 The vectors were provided by Drs Gerald Levy and Wendell Weber, University of Michigan. For the current work, the NruI/SmaI fragment of 2.9 kb was purified for injection with these constructs designated as pCMV-NAT1 or 2. Another construct was made in order to possibly enhance liver expression: the 400 bp a 1 antitrypsin BglII fragment from pAM307, 43 provided by Dr Kotoku Kurochi, was inserted symmetrically into the BamH1 site located between the CMV promoter and the NAT1 cDNA. The correct orientation and structure were determined by sequencing for all constructs. This 3.3 kb NruI/SmaI fragment was prepared from this plasmid, named pCMV-HAAT-NAT1, for injection. Injection was performed by the Genetically Modified Mouse Service of the University of Arizona into C57BL/ 6J Â DBA/2J F 2 zygotes by standard techniques (F 1 parents are used to avoid the two-cell block to development). Animals were maintained at the University of Arizona Animal Care Facility according to the criteria outlined in the 'Guide for the Care and Use of Laboratory Animals' (PHS Assurance No. A3248-01) on mouse chow containing 6% fat (or 10% for breeding mothers) and water ad libitum. Positive transgenics and their progeny were identified by PCR using promoter-specific forward primers and NAT1-or NAT2-specific reverse primers (Table 1) . PCR conditions were as follows: 3 min initial denaturation at 951C and 35 cycles of 951C for 30 s, 581C for 30 s and 721C for 1 min in a Peltier Thermal cycler (MJ Research, Inc., USA). The reaction mixture of 25 ml final volume contained 25 pmol primers, 2.5 mM MgCl 2 and 1.25 U Taq DNA polymerase (PIERCE). Mice were backcrossed to C57BL/6J for the indicated number of generations. At N12, transgenic positive males and females were intercrossed in an attempt to establish a homozygous line.
All mice were maintained at the University of Arizona Animal Care Facility (PHS Assurance No. A-3248-01) on mouse chow containing 6% fat (or 10% for breeding mothers) and water ad libitum. They were kept on a 14 h light, 10 h dark, light cycle.
Determination of Copy Number
Quantitative PCR was performed (Smart Cycler system by Cepheid, Sunnyvale, CA, USA) in a 25 ml mixture containing 1 Â SYBR Green I (Molecular Probes), 1 Â PCR buffer (Applied Biosystems), 2.5 mM MgCl 2 , 15-25 pmol of each primer (Table 1 ) and 1 ml of extracted DNA (25-100 ng). The reaction was performed with an initial denaturation for 10 min at 951C, followed by 40 cycles of denaturation for 30 s, annealing at the indicated temperature (Table 1) for 30 s and extension at 721C for 1 min. The specificity of each amplification was subjected to a melt curve analysis ramping for 21C/s from 62 to 951C. The concentration of plasmid DNA was measured at 260 nm. The copies were calculated and serially diluted to 10 3 copies. The standard curve is performed in the dilution range of 100, 50, 10, five, two and one copies of plasmid coamplified with the genomic DNA.
NAT Activity
Adult C57BL6/J and transgenic mice were killed by CO 2 asphyxiation. Livers, lungs, kidneys and brains were removed, homogenized and cytosol fractions prepared. 41 NAT activities were determined using PABA and INH. These represent isoform-selective substrates of NATs. Activities were determined under initial velocity conditions, using an acetylcoenzyme A recycling system. 44 The assay consisted of 15 mM acetylcarnitine, 2 U of carnitine acetyltransferase/ml, 2 mM EDTA, 2 mM dithioerythitol, 50 mM Tris-HCl, pH 7.5, 0.5 mg cytosolic protein, 0.5 mM acetylcoenzyme A and 44.4 mM substrate. Following 10 min at 371C, the reaction was stopped with ice-cold methanol or trichloroacetic acid. For PABA, reverse-phase HPLC was used to separate the acetyl product from the parent compound. 45, 46 The samples were eluted from an Adsorbosil C18 column with 13% acetonitrile in water containing 0.5% acetic acid. The amount of acetyl INH was determined by spectrophotometry. 47 The NAT reaction was stopped with 10% trichloroacetic acid, the supernatant was mixed with 0.8 M potassium borate, pH 8.0 and the absorbance measured 303 nm. For each compound, the amount of acetyl product was calculated from a standard curve and activity expressed as nmol product/mg protein/min. Comparisons of activity were performed by an analysis of variance, followed by the Student-Newman-Keuls Q-test or Student's t-test.
mRNA Determinations Tissue samples
Adult lung, kidney, brain and liver were immediately frozen in liquid nitrogen. Total RNA was extracted using TRIazol Reagent (Invitrogen) according to the manufacturer's instructions. Genomic DNA potentially present in RNA samples was removed by incubating the RNA with RNasefree DNase I (Promega). RNA quantification was performed by spectrophotometry at 260 nm, and integrity of the RNA was verified by electrophoresis of 1 mg of total RNA on a 1.2% agarose gel stained with ethidium bromide.
Quantitative RT-PCR Total RNA (2 mg) was reverse-transcribed into first-strand cDNA using TaqMan Reverse Transcription Reagents (Applied Biosystems, Roche). Primers and conditions are described in Table 4 . The GAPDH primer is located in different exons such that only that in RNA is amplified. In order to optimize the conditions, a 10 Â SYBR Green I master mixture of 100 mM Tris-HCl, pH 8.5, 500 mM KCl, 25 mM MgCl 2 and 1.5% X-100 was used. 48 RT-PCR was performed using a thermal cycler system (Cepheid, USA). The reactions were performed in a 25 ml volume, with different primer concentrations and different annealing temperatures (Table  1) . A typical protocol included a 300 s denaturation step, followed by 45 cycles with a 951C denaturation for 30 s, annealing for 30 s and 721C extension for 1 min. To confirm amplification specificity, the PCR products from each primer pair were subjected to a melting curve analysis and subsequent agarose gel electrophoresis. All experiments were performed at least three times (with separate RNA preparation). For the standard curve, 2-5-fold serial dilutions were made starting from the original concentration. The dynamic range of the standard curve spanned at least five orders of magnitude. 
